Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guobang PharmaSHSE:605507 +0.06%88 EBITDA Margin % is 12.91% as of Mar. 2026, which is 44% below its 10-year median of 22.89. GuruFocus rates SHSE:605507 with a GF Score™ of 88/100 and a GF Value™ of ¥16.00 (Fairly Valued). The stock has 4 warning signs investors should review. Among 960 Drug Manufacturers companies, Guobang Pharma ranks better than 56.56% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Guobang Pharma's EBITDA for the
three
months ended in Mar. 2026 was ¥196 Mil. Guobang Pharma's Revenue for the
three
months ended in Mar. 2026 was ¥1,521 Mil. Therefore, Guobang Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was 12.91%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Guobang Pharma EBITDA Margin % Related Terms
Guobang Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Guobang Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Guobang Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guobang Pharma EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Guobang Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Guobang Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guobang Pharma (SHSE:605507) has a EBITDA Margin % of 12.91% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Guobang Pharma and its competitors. This is 44% below median its historical median of 22.89. Over the past decade, Guobang Pharma's EBITDA Margin % has ranged from 15.05 to 27.01. According to the industry distribution chart, Guobang Pharma ranks #417 out of 960 companies in the Drug Manufacturers industry, placing it in the top 43.4%.
Is Guobang Pharma's EBITDA Margin % too high?
Guobang Pharma's current EBITDA Margin % of 12.91% is 44% below median its 10-year median of 22.89. Over the past 10 years, this metric has ranged from a low of 15.05 to a high of 27.01. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Guobang Pharma's value of 12.91% is 3.2% above this industry median. Based on the distribution chart, Guobang Pharma ranks #417 out of 960 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Guobang Pharma has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Guobang Pharma's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Guobang Pharma ranks #417 out of 960 companies for EBITDA Margin %. This puts Guobang Pharma in the upper half of its industry. The industry median EBITDA Margin % is 12.52. Guobang Pharma's value of 12.91% is 3.2% above this benchmark. Historically, Guobang Pharma's own EBITDA Margin % has ranged from 15.05 to 27.01 over the past decade. While the company's 10-year median is 22.89 vs. the industry median of 12.52, Guobang Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guobang Pharma's current EBITDA Margin % of 12.91% is 3.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Guobang Pharma and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guobang Pharma's current EBITDA Margin % is 12.91%, which is 44% below median its own 10-year median of 22.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guobang Pharma stock overvalued right now?
Based on GuruFocus' analysis, Guobang Pharma (SHSE:605507) is currently considered Fairly Valued. The stock's GF Value™ is ¥16.00, compared to a current price of ¥16.30 — trading 1.9% above its estimated fair value. The current EBITDA Margin % is 12.91%, which is 44% below median its 10-year median of 22.89 and 3.2% above the Drug Manufacturers industry median of 12.52. Guobang Pharma's overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Guobang Pharma (SHSE:605507), the current EBITDA Margin % is 12.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guobang Pharma (SHSE:605507) Overvalued in 2026?
Based on GuruFocus' analysis, Guobang Pharma stock appears to be overvalued.
The current stock price of ¥16.30 is trading 1.9% above its estimated GF Value™ of ¥16.00.
GuruFocus considers Guobang Pharma to be Fairly Valued.
Key valuation signals for SHSE:605507:
EBITDA Margin %: 12.91% (44% below median its 10-year median of 22.89)
GF Value™: ¥16.00 vs. price of ¥16.30 (1.9% above fair value)
Industry Position: 3.2% above the Drug Manufacturers median (#417 of 960)
No single metric tells the full story. See the SHSE:605507 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guobang Pharma Ltd is engaged in the research and development, production and sales of related products in the field of medicine and animal health products.
88GF Score
Get the complete analysis for SHSE:605507
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605507 has been successfully added to your 
